Categories

Myriad Genetics Announces Global Expansion of Myriad myChoice® Tumor Testing in Europe and China SALT LAKE CITY, Nov. 16, 2020 (GLOBE… Continue Reading

German Federal Joint Committee (G-BA) Issues Nationwide Reimbursement Decision for EndoPredict® Breast Cancer Prognostic Test October 16, 2020 at 9:05 AM…

Continue Reading

SALT LAKE CITY, Aug. 21, 2020 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in molecular diagnostics and…

Continue Reading

Publications Demonstrate the Ability of the PRS Component of riskScore® to Accurately Stratify Breast Cancer Risk in Women Both With and…

Continue Reading

SALT LAKE CITY, June 25, 2020 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision…

Continue Reading

EndoPredict Predicts Response to Neoadjuvant Chemotherapy and Endocrine Therapy SALT LAKE CITY, June 04, 2020 (GLOBE NEWSWIRE) — Myriad Genetics, Inc.…

Continue Reading

SALT LAKE CITY, May 29, 2020 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision…

Continue Reading

SALT LAKE CITY, May 20, 2020 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision…

Continue Reading

SALT LAKE CITY, May 11, 2020 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision…

Continue Reading

More Than 25,000 People in Japan Are Eligible for Genetic Testing SALT LAKE CITY, April 06, 2020 (GLOBE NEWSWIRE) — Myriad…

Continue Reading